Advanced Therapies Manufacturing Strategy Digital 

Assess the current manufacturing landscape in the context of the COVID-19 pandemic. What are the short and long term implications for advanced therapeutics development?

July 14 - 15, 2020 | Virtual Event

Meet the Speakers

View the event program for additional information on speakers, sessions, networking activities, and more!

Speakers


Peter Marks MD, PhD
Peter Marks MD, PhD
Director, Center for Biologics Evaluation and Research (CBER)
Food and Drug Administration (FDA)
Steven Goodman
Steven Goodman
Head of Drug Product Manufacturing
Bluebird Bio
Mark Plavsic
Mark Plavsic
Chief Technology Officer and Head of Nonclinical Development
LYSOGENE
Kelvin H. Lee
Kelvin H. Lee
Institute Director
National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
Craig Malzahn
Craig Malzahn
Vice President, Manufacturing and Supply Chain
REGENXBIO Inc.
Rick Silva PhD
Rick Silva PhD
Executive Director, Clinical, Translation and Industry Collaborations
Texas A&M Health Science Center
Vlad Hogenhuis
Vlad Hogenhuis
Chief Operating Officer (fmr.)
Ultragenyx
Michael Lehmicke
Michael Lehmicke
Director, Science and Industry Affairs
Alliance for Regenerative Medicine